Found 698 none trials
A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways. AMX0035 is not approved …
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.
Hydrocephalus is a medical condition in which an abnormal buildup of cerebrospinal fluid (CSF) causes the fluid-filled spaces of the brain, the ventricles, to become enlarged. Enlarged ventricles and increased intracranial pressure can cause headaches, dizziness, blurred vision, cognitive impairment, gait disturbances and in severe cases even brain herniation or …
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant …
We plan to enroll up to 16 adult subjects in this study. We will enroll up to 8 patients with a diagnosis of probable idiopathic Parkinsons Disease (PD cohort) and up to 8 age and gender matched Healthy Controls (HC cohort). PET/CT imaging will be used to evaluate neuroinflammation in …
Our study is a Phase 1Ib/2 clinical trial to evaluate the safety and feasibility of the combination of radiotherapy (RT) in a single fraction of 7 Gy with pembrolizumab in patients with operable breast cancer. We will employ a Simon Two Stage design to evaluate the safety, feasibility, and efficacy …
